- A 2024 review summarized more than 30 trials and over 11,000 human subjects.
- A 2023 COVID-19 meta-analysis found no statistically significant overall mortality effect.
- A 2025 sepsis meta-analysis found an overall signal, but higher-quality and multicenter subgroups did not show statistically significant benefit.
RESEARCH REBEL • EVIDENCE DOSSIER
Thymosin Alpha-1
SUBSTANTIAL HUMAN LITERATURE • INDICATION-SPECIFICAn immunomodulatory peptide with substantially more human literature than many community research peptides. Results are heterogeneous by disease and study quality.
- Which populations derive clinically meaningful benefit across proposed uses.
- How wellness/community use maps to disease-specific trials.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
Published regimens remain attached to disease, population, route and trial; there is no single universal Research Rebel protocol.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community reports often describe immune-support and recovery goals; these remain separate from clinical endpoints.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED